Klebsiella pneumoniae

Klebsiella pneumoniae
Name	Klebsiella pneumoniae
Domain	Bacteria
Phylum	Proteobacteria
Classis	Gammaproteobacteria
Ordo	Enterobacterales
Familia	Enterobacteriaceae
Genus	Klebsiella
Species	K. pneumoniae

Klebsiella pneumoniae is a gram-negative, encapsulated bacillus implicated in community-acquired and nosocomial infections. First described in the late 19th century, it has become notable for hospital outbreaks and multidrug-resistant strains. Surveillance by public health organizations and research institutions highlights its role in pneumonia, urinary tract infections, and bloodstream infections.

Taxonomy and Classification

Klebsiella pneumoniae is classified within the phylum Proteobacteria, class Gammaproteobacteria, order Enterobacterales, and family Enterobacteriaceae, a lineage that includes medically relevant genera such as Escherichia coli, Salmonella, Shigella, and Yersinia. Taxonomic revisions involving biochemical, phylogenomic, and multilocus sequence typing studies have been reported by groups associated with institutions like the Centers for Disease Control and Prevention, the World Health Organization, and university bacterial taxonomy centers. Clinical microbiology reference texts and culture collections at the American Type Culture Collection provide strain designations and type strains used in comparative genomics and epidemiology.

Morphology and Physiology

K. pneumoniae appears as non-motile, rod-shaped cells surrounded by a prominent polysaccharide capsule observable in classical descriptions by early microbiologists and in modern electron microscopy studies hosted by laboratories at the Pasteur Institute and the National Institutes of Health. It grows on common bacteriological media used in clinical laboratories at hospitals affiliated with medical centers such as Johns Hopkins Hospital and Mayo Clinic, exhibiting mucoid colonies associated with hypercapsulation phenotypes studied in academic centers including Harvard Medical School and University of Oxford. Metabolic profiling and biochemical tests referenced in manuals from the Clinical and Laboratory Standards Institute and the European Committee on Antimicrobial Susceptibility Testing distinguish it from related taxa.

Virulence Factors and Pathogenesis

Key virulence determinants include the polysaccharide capsule, lipopolysaccharide O antigens, siderophore systems such as enterobactin and yersiniabactin, and fimbrial adhesins; these factors have been characterized in research collaborations involving the Wellcome Trust, the Gates Foundation, and tertiary research hospitals. Hypervirulent lineages carrying rmpA and rmpA2 regulators and plasmids encoding virulence and resistance genes were reported in case series from metropolitan centers like Seoul National University Hospital and University of California, San Francisco. Animal model experiments conducted at institutes such as the National Institute of Allergy and Infectious Diseases and comparative genomic analyses by consortia including the European Molecular Biology Laboratory illuminate mechanisms of immune evasion and tissue tropism.

Clinical Manifestations and Epidemiology

K. pneumoniae causes pneumonia, urinary tract infection, intra-abdominal infection, bacteremia, and liver abscess; case reports and cohort studies published from tertiary referral centers including Mount Sinai Hospital, Karolinska University Hospital, and St Thomas' Hospital document severe disease in elderly and immunocompromised patients. Epidemics in intensive care units and outbreaks associated with ventilator-associated pneumonia and central line-associated bloodstream infections have been investigated by infection control teams at the National Health Service and the Centers for Disease Control and Prevention. Global surveillance projects coordinated by the World Health Organization and regional public health agencies track prevalence and clonal spread across continents including reports from India, China, United States, Brazil, and South Africa.

Diagnosis and Laboratory Identification

Diagnosis relies on culture from clinical specimens processed in clinical laboratories at hospitals such as Cleveland Clinic and university centers guided by standards from the Clinical and Laboratory Standards Institute. Identification methods include biochemical assays, automated systems produced by companies like bioMérieux and BD (Becton, Dickinson and Company), matrix-assisted laser desorption/ionization time-of-flight mass spectrometry used in reference labs, and nucleic acid amplification tests developed by research groups at institutions such as Karolinska Institutet and University of Tokyo. Molecular typing methods—PFGE, MLST, and whole-genome sequencing—are employed by public health laboratories at the European Centre for Disease Prevention and Control and national sequencing consortia.

Treatment, Antimicrobial Resistance, and Infection Control

Treatment is guided by antimicrobial susceptibility profiles interpreted using guidelines from the Infectious Diseases Society of America and the European Society of Clinical Microbiology and Infectious Diseases. Rising prevalence of extended-spectrum beta-lactamases, carbapenemases (including KPC and NDM), and colistin resistance has been documented in surveillance reports from the Centers for Disease Control and Prevention, the World Health Organization, and national reference laboratories. Antimicrobial stewardship programs in hospitals like Massachusetts General Hospital and infection control measures recommended by the World Health Organization and national health services focus on hand hygiene, contact precautions, environmental cleaning, and outbreak investigation protocols coordinated by hospital epidemiology teams.

Prevention and Vaccination Strategies

Prevention includes standard infection prevention measures implemented in health systems such as the National Health Service and vaccination research initiatives supported by funders like the Bill & Melinda Gates Foundation and the Wellcome Trust. Vaccine development efforts targeting capsular polysaccharide antigens and conserved proteins have been pursued by academic laboratories at institutions such as University of Oxford, Imperial College London, and biotechnology companies collaborating with regulatory agencies including the European Medicines Agency and the U.S. Food and Drug Administration. Public health campaigns and international collaborations coordinate surveillance, antimicrobial stewardship, and research priorities to limit spread in communities and healthcare settings.

Category:Bacteria